The Valley Desk

Clinical trial reportEuropean journal of cancer (Oxford, England : 1990)Published

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study

16 of 35 authors shown in byline order.

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
European journal of cancer (Oxford, England : 1990)
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Acrylamides; Aniline Compounds; Morpholines; Pyrimidines; Indoles; Quinazolines; Antineoplastic Combined Chemotherapy Protocols; Protein Kinase Inhibitors; Treatment Outcome
PubMed ID
40730077
Added to directory
Source checked

Report a correction or request removal